Cancer immune therapy using engineered ⠉tail-flipping⠒ nanoliposomes targeting alternatively activated macrophages

HIGHLIGHTS

SUMMARY

Received: 1 February 2021 Check for updates Praneeth R. Kuninty1,7, Karin Binnemars-Postma1,7, Ahmed Jarray 2,3, Kunal P. Pednekar1, Marcel A. Heinrich 1, Helen J. Pijffers 1, Hetty ten Hoopen1, Gert Storm1,4,5, Peter van Hoogevest6, Wouter K. den Otter 2 and amp; Jai Prakash 1 Alternatively-activated, M2-like tumor-associated macrophages (TAM) strongly contribute to tumor growth, invasiveness and metastasis. The TME is enriched with a variety of immune cells such as tumor-associated macrophages (TAM), T-lymphocytes, natural killer cells as well as other cells including cancer . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.